Finlayson CA - Search Results

1

Enhanced insulin signaling via Shc in human breast cancer.

Finlayson CA, Chappell J, Leitner JW, Goalstone ML, Garrity M, Nawaz S, Ciaraldi TP, Draznin B. Finlayson CA, et al. Metabolism. 2003 Dec;52(12):1606-11. doi: 10.1016/s0026-0495(03)00311-1. Metabolism. 2003. PMID: 14669164

2

Hepatic complications of breast cancer.

Diamond JR, Finlayson CA, Borges VF. Diamond JR, et al. Among authors: finlayson ca. Lancet Oncol. 2009 Jun;10(6):615-21. doi: 10.1016/S1470-2045(09)70029-4. Lancet Oncol. 2009. PMID: 19482250 Review.

3

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Kabos P, et al. Among authors: finlayson c. Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24. Breast Cancer Res Treat. 2012. PMID: 22821401 Free PMC article.

4

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.

Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Harvell DM, et al. Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9. Breast Cancer Res Treat. 2008. PMID: 18327671 Clinical Trial.

5

Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.

Singh M, Capocelli KE, Marks JL, Schleicher RB, Finlayson CA, Seligman PA. Singh M, et al. Among authors: finlayson ca. Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):147-56. doi: 10.1097/01.pai.0000137364.36091.b0. Appl Immunohistochem Mol Morphol. 2005. PMID: 15894927

6

A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer.

Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. Brooks G, et al. Oncology (Williston Park). 2008 Oct;22(11):1270-6. Oncology (Williston Park). 2008. PMID: 18980024 No abstract available.

7

A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score.

Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. Bowles DW, et al. Oncology (Williston Park). 2007 Sep;21(10):1212-7. Oncology (Williston Park). 2007. PMID: 17926799 Free article. No abstract available.

8

Ultrasound can estimate the pathologic size of infiltrating ductal carcinoma.

Finlayson CA, MacDermott TA. Finlayson CA, et al. Arch Surg. 2000 Feb;135(2):158-9. doi: 10.1001/archsurg.135.2.158. Arch Surg. 2000. PMID: 10668873

9

A woman with primary breast cancer and a solitary sternal metastasis.

Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Elias A. Menter A, et al. Oncology (Williston Park). 2006 Aug;20(9):1068-71, 1075, 1079-80. Oncology (Williston Park). 2006. PMID: 16986350 Free article. No abstract available.

10

A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining.

Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. Urquhart A, et al. Oncology (Williston Park). 2005 Mar;19(3):278, 283-4, 287 passim. Oncology (Williston Park). 2005. PMID: 15828548 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters